HepatoSCRIPT combines scientists and clinicians with expertise in cancer, immunology, metabolism, liver biology and beyond state-of-the-art technologies.
Our ambition is to increase our knowledge of the pathophysiology of hepatocellular carcinoma in obesity.
Liver cancer is the fourth most common cause of cancer-related death worldwide.
In Belgium, liver cancer is the 8th most frequent cause of cancer-related deaths in females and the 10th in males (Belgian Cancer Registry). Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers and is refractory to almost all currently available anticancer therapies, with a 5-year survival rate of approximately 15%.
The consortium
We aim to expand our knowledge of the mechanisms underlying hepatocellular carcinoma in the context of obesity. The HepatoSCRIPT team comprises experts in cancer, immunology, metabolism, liver biology, and cutting-edge technologies.